Novartis gets approval for Reclast, a once-per-year osteoporosis treatment. That's a game-changer - very cool advance that should lead to far better patient compliance. A long-ish article on Wyeth's …
Game-changing Drugs
This week, Novartis got U.S. approval for Reclast, a once-yearly treatment for osteoporosis. A fifteen minute infusion, once a year - talk about convenience and better patient compliance! Very cool. …
Pharma News 8_17
Amgen finally feels the heat from declining market demand; big cuts coming. Novartis takes a hit on Prexige (COX-2 inhibitor); withdrawn in Australia. New cancer killers? Electric fields, gene …
Pharma News 8_3
A minor comeback for Novartis' Zelnorm. Avandia gets a reprieve, of sorts...to remain on the market, but undoubtedly with a raft of warnings and cautions. Meanwhile, more encouraging data on Actos, …
Pharma News 7_27
Two weeks worth of news articles linked here: Medical News Actos: safer than Avandia? Cialis going toward a once-daily version (but shouldn't it be once every day-and-a-half??) Novartis gets some …
Pharma News 7_13
Merck investing even more in its cancer portfolio - a growing trend among the top pharma companies. Takeda seeking to grow its Amitiza franchise, now that Novartis' Zelnorm has been pulled from the …